A recent population-based study, published in CANCER, a peer-reviewed journal of the American Cancer Society, has brought into sharp focus…
Read More
Genetic Mapping Reveals Explosive Growth of Chronic Myeloid Leukemia Years Before Clinical Diagnosis and Challenges Current Treatment Paradigms
A landmark study from the Wellcome Sanger Institute and a consortium of international collaborators has provided an unprecedented look into…
Read More
Novel Combination Therapy Offers Breakthrough Strategy for Overcoming Differentiation Blockade in Acute Myelogenous Leukemia
Acute Myelogenous Leukemia (AML) remains one of the most formidable challenges in modern oncology, characterized by its rapid progression and…
Read More
Rising Therapy-Related Leukemia Rates Signal New Testing Demands for Clinical Labs
The study, conducted by researchers analyzing extensive data from the Osaka Cancer Registry in Japan, provides a robust and concerning…
Read More
Explosive Growth and Early Origins of Chronic Myeloid Leukemia Revealed in Landmark Genomic Study
A pioneering research project led by the Wellcome Sanger Institute has fundamentally altered the scientific understanding of chronic myeloid leukemia…
Read More
Breakthrough Combination Therapy Targets Cellular Differentiation Blocks to Provide New Treatment Pathway for Acute Myelogenous Leukemia
In a significant advancement for hematological oncology, researchers from Ludwig Cancer Research have unveiled a novel therapeutic strategy aimed at…
Read More
Rising Therapy-Related Leukemia Rates Signal New Testing Demands for Clinical Labs
A recent population-based study, published in CANCER, a journal of the American Cancer Society, has issued a significant alert to…
Read More
Rapid Evolution and Explosive Growth of Chronic Myeloid Leukemia Revealed by Genomic Mapping
A landmark study published in the journal Nature has fundamentally altered the scientific understanding of chronic myeloid leukemia (CML), revealing…
Read More
Ludwig Cancer Research Study Reveals Novel Combination Therapy for Acute Myelogenous Leukemia Targeting Epigenetic Barriers to Cell Differentiation
A collaborative international study led by researchers at Ludwig Cancer Research has identified a breakthrough therapeutic strategy for acute myelogenous…
Read More
Merck & Co. Acquires Terns Pharmaceuticals, Bolstering Chronic Myeloid Leukemia Pipeline with FDA Breakthrough Designation for TERN-701
Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read MoreYOU MAY HAVE MISSED
